Sponsor:
PDS Biotechnology Corp.
Code:
NCT06790966
Conditions
Recurrent Head and Neck Cancer
Metastatic Head and Neck Cancer
HPV Positive Oropharyngeal Squamous Cell Carcinoma
Neoplasms, Head and Neck
Unresectable Head and Neck Squamous Cell Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Combination Treatment of PDS0101 and Pembrolizumab
Pembrolizumab Monotherapy
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by PDS Biotechnology Corp. on 2025-03-25.